CoChat
Sign Up
Cited by 387Cancer Immunotherapy and BiomarkersBladder and Urothelial Cancer TreatmentsGlycosylation and Glycoproteins Research

Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer

Open access
Hu, Jiao, Yu, Anze, Othmane, Belaydi, Qiu, Dongxu, Li, Huihuang, Li, Chao, Liu, Peihua, Ren, Wenbiao +6 more·2021·Theranostics
DOI 10.7150/thno.53649PMC PMC7847675
Open this paper in CoChat — free account

Abstract

Anti-Siglec15 immunotherapy might be suitable for BLCA treatment as Siglec15 correlates with a non-inflamed TME in BLCA. Siglec15 could also predict the molecular subtype and the response to several treatment options.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7150/thno.53649

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • TBX3 expression is significantly higher in cancer tissues than in normal tissues in both the Xiangya cohort and the TCGA-BLCA cohort.

    “Based on bulk RNA-seq data, we found that TBX3 was expressed significantly higher in cancer tissues as compared to normal tissues in both the Xiangya cohort 34,38 (Figure 1A) and TCGA-BLCA cohort (Figure 1B).”

    From TBX3 shapes an immunosuppressive microenvironment and induces immunotherapy resistance (2025) · cites this paper as [38]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 54

  1. [2]Witjes JA Bruins HM Cathomas R Compérat EM Cowan NC Gakis G European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines Eur Urol 2020 79 82 104 32360052
  2. [3]Rosenberg JE Hoffman-Censits J Powles T van der Heijden MS Balar AV Necchi A Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial Lancet 2016 387 1909 20 26952546 PMC5480242
  3. [4]Sharma P Retz M Siefker-Radtke A Baron A Necchi A Bedke J Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial Lancet Oncol 2017 18 312 22 28131785
  4. [5]Kandoth C McLellan MD Vandin F Ye K Niu B Lu C Mutational landscape and significance across 12 major cancer types Nature 2013 502 333 9 24132290 PMC3927368
  5. [7]Gajewski TF Corrales L Williams J Horton B Sivan A Spranger S Cancer immunotherapy targets based on understanding the T cell-inflamed versus non-T cell-inflamed tumor microenvironment Adv Exp Med Biol 2017 1036 19 31 29275462 PMC6693322
  6. [8]Ji RR Chasalow SD Wang L Hamid O Schmidt H Cogswell J An immune-active tumor microenvironment favors clinical response to ipilimumab Cancer Immunol Immunother 2012 61 1019 31 22146893 PMC11028506
  7. [10]Maleki Vareki S High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors J Immunother Cancer 2018 6 157 30587233 PMC6307306
  8. [11]Spranger S Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment Int Immunol 2016 28 383 91 26989092 PMC4986232
  9. [12]Palakurthi S Kuraguchi M Zacharek SJ Zudaire E Huang W Bonal DM The combined effect of FGFR inhibition and PD-1 blockade promotes tumor-intrinsic induction of antitumor immunity Cancer Immunol Res 2019 7 1457 71 31331945
  10. [13]Korpal M Puyang X Jeremy Wu Z Seiler R Furman C Oo HZ Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer Nat Commun 2017 8 103 28740126 PMC5524640
  11. [14]Spranger S Bao R Gajewski TF Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity Nature 2015 523 231 5 25970248
  12. [15]Sweis RF Spranger S Bao R Paner GP Stadler WM Steinberg G Molecular drivers of the non-T-cell-inflamed tumor microenvironment in urothelial bladder cancer Cancer Immunol Res 2016 4 563 8 27197067 PMC4943758
  13. [16]Nagarsheth N Wicha MS Zou W Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy Nat Rev Immunol 2017 17 559 72 28555670 PMC5731833
  14. [17]McLaughlin J Han G Schalper KA Carvajal-Hausdorf D Pelekanou V Rehman J Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer JAMA Oncol 2016 2 46 54 26562159 PMC4941982
  15. [19]Kamoun A de Reyniès A Allory Y Sjödahl G Robertson AG Seiler R A consensus molecular classification of muscle-invasive bladder cancer Eur Urol 2020 77 420 33 31563503 PMC7690647
  16. [20]Wang J Sun J Liu LN Flies DB Nie X Toki M Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy Nat Med 2019 25 656 66 30833750 PMC7175920
  17. [21]Angata T Tabuchi Y Nakamura K Nakamura M Siglec-15: an immune system Siglec conserved throughout vertebrate evolution Glycobiology 2007 17 838 46 17483134
  18. [22]Li B Zhang B Wang X Zeng Z Huang Z Zhang L Expression signature, prognosis value, and immune characteristics of Siglec-15 identified by pan-cancer analysis Oncoimmunology 2020 9 1807291 32939323 PMC7480813
  19. [23]Goldman MJ Craft B Hastie M Repečka K McDade F Kamath A Visualizing and interpreting cancer genomics data via the Xena platform Nat Biotechnol 2020 38 675 8 32444850 PMC7386072
  20. [24]Bonneville R Krook MA Kautto EA Miya J Wing MR Chen HZ Landscape of microsatellite instability across 39 cancer types JCO Precis Oncol. 2017 2017 PMC5972025 29850653
  21. [25]Vasaikar SV Straub P Wang J Zhang B LinkedOmics: analyzing multi-omics data within and across 32 cancer types Nucleic Acids Res 2018 46 D956 D63 29136207 PMC5753188
  22. [27]Mariathasan S Turley SJ Nickles D Castiglioni A Yuen K Wang Y TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells Nature 2018 554 544 8 29443960 PMC6028240
  23. [28]Charoentong P Finotello F Angelova M Mayer C Efremova M Rieder D Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade Cell Rep 2017 18 248 62 28052254
  24. [29]Chen DS Mellman I Oncology meets immunology: the cancer-immunity cycle Immunity 2013 39 1 10 23890059
  25. [30]Xu L Deng C Pang B Zhang X Liu W Liao G TIP: a web server for resolving tumor immunophenotype profiling Cancer Res 2018 78 6575 80 30154154
  26. [31]Ru B Wong CN Tong Y Zhong JY Zhong SSW Wu WC TISIDB: an integrated repository portal for tumor-immune system interactions Bioinformatics 2019 35 4200 2 30903160
  27. [32]Li T Fu J Zeng Z Cohen D Li J Chen Q TIMER2.0 for analysis of tumor-infiltrating immune cells Nucleic Acids Res 2020 48 W509 W514 32442275 PMC7319575
  28. [33]Finotello F Mayer C Plattner C Laschober G Rieder D Hackl H Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data Genome Med 2019 11 34 31126321 PMC6534875
  29. [34]Becht E Giraldo NA Lacroix L Buttard B Elarouci N Petitprez F Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression Genome Biol 2016 17 218 27765066 PMC5073889
  30. [35]Li B Severson E Pignon JC Zhao H Li T Novak J Comprehensive analyses of tumor immunity: implications for cancer immunotherapy Genome Biol 2016 17 174 27549193 PMC4993001
  31. [36]Newman AM Liu CL Green MR Gentles AJ Feng W Xu Y Robust enumeration of cell subsets from tissue expression profiles Nat Methods 2015 12 453 7 25822800 PMC4739640
  32. [37]Auslander N Zhang G Lee JS Frederick DT Miao B Moll T Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma Nat Med 2018 24 1545 9 30127394 PMC6693632
  33. [38]Ayers M Lunceford J Nebozhyn M Murphy E Loboda A Kaufman DR IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade J Clin Invest 2017 127 2930 40 28650338 PMC5531419
  34. [40]Kato S Goodman A Walavalkar V Barkauskas DA Sharabi A Kurzrock R Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate Clin Cancer Res 2017 23 4242 50 28351930 PMC5647162
  35. [42]Hu J Li H He T Deng H Gong G Cui Y A nomogram incorporating PD-L1, NLR, and clinicopathologic features to predict inguinal lymph node metastasis in penile squamous cell carcinoma Urol Oncol 2020 38 641.e19 e29 32389428
  36. [44]Van Allen EM Mouw KW Kim P Iyer G Wagle N Al-Ahmadie H Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma Cancer Discov 2014 4 1140 53 25096233 PMC4238969
  37. [45]Groenendijk FH de Jong J Fransen van de Putte EE Michaut M Schlicker A Peters D ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy Eur Urol 2016 69 384 8 25636205
  38. [46]Pietzak EJ Zabor EC Bagrodia A Armenia J Hu W Zehir A Genomic differences between "Primary" and "Secondary" muscle-invasive bladder cancer as a basis for disparate outcomes to cisplatin-based neoadjuvant chemotherapy Eur Urol 2019 75 231 9 30290956 PMC6339572
  39. [47]Singla N Ghandour RA Raj GV Biomarkers for platinum sensitivity in bladder cancer: are we there yet? Transl Androl Urol 2019 8 S236 S9 31392132 PMC6642961
  40. [48]Nadal R Bellmunt J Management of metastatic bladder cancer Cancer Treat Rev 2019 76 10 21 31030123
  41. [49]Robertson AG Kim J Al-Ahmadie H Bellmunt J Guo G Cherniack AD Comprehensive molecular characterization of muscle-invasive bladder cancer Cell 2017 171 540 56.e25 28988769 PMC5687509
  42. [50]Rebouissou S Bernard-Pierrot I de Reyniès A Lepage ML Krucker C Chapeaublanc E EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype Sci Transl Med 2014 6 244ra91 25009231
  43. [51]Sjödahl G Lauss M Lövgren K Chebil G Gudjonsson S Veerla S A molecular taxonomy for urothelial carcinoma Clin Cancer Res 2012 18 3377 86 22553347
  44. [52]Choi W Porten S Kim S Willis D Plimack ER Hoffman-Censits J Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy Cancer Cell 2014 25 152 65 24525232 PMC4011497
  45. [53]Damrauer JS Hoadley KA Chism DD Fan C Tiganelli CJ Wobker SE Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology Proc Natl Acad Sci U S A 2014 111 3110 5 24520177 PMC3939870
  46. [54]Mo Q Nikolos F Chen F Tramel Z Lee YC Hayashi K Prognostic power of a tumor differentiation gene signature for bladder urothelial carcinomas J Natl Cancer Inst 2018 110 448 59 29342309 PMC6279371
  47. [55]Jiang P Gu S Pan D Fu J Sahu A Hu X Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response Nat Med 2018 24 1550 8 30127393 PMC6487502
  48. [56]Necchi A Raggi D Gallina A Ross JS Farè E Giannatempo P Impact of molecular subtyping and immune infiltration on pathological response and outcome following neoadjuvant pembrolizumab in muscle-invasive bladder cancer Eur Urol 2020 77 701 10 32165065
  49. [57]McConkey DJ Choi W Shen Y Lee I-L Porten S Matin SF A prognostic gene expression signature in the molecular classification of chemotherapy-naive urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy: a phase 2 trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with bevacizumab in urothelial cancer Eur Urol 2016 69 855 62 26343003 PMC4775435
  50. [60]Sanmamed MF Chen L A paradigm shift in cancer immunotherapy: from enhancement to normalization Cell 2018 175 313 26 30290139 PMC6538253
  51. [62]van Dijk N Funt SA Blank CU Powles T Rosenberg JE van der Heijden MS The cancer immunogram as a framework for personalized immunotherapy in urothelial cancer Eur Urol 2019 75 435 44 30274701 PMC6697269
  52. [63]Hodi FS Chesney J Pavlick AC Robert C Grossmann KF McDermott DF Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial Lancet Oncol 2016 17 1558 68 27622997 PMC5630525
  53. [65]Eckstein M Strissel P Strick R Weyerer V Wirtz R Pfannstiel C Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy J Immunother Cancer 2020 8 e000162 32448798 PMC7253053
  54. [66]Woerl AC Eckstein M Geiger J Wagner DC Daher T Stenzel P Deep learning predicts molecular subtype of muscle-invasive bladder cancer from conventional histopathological slides Eur Urol 2020 78 256 64 32354610

Cited by

Sorted by citations

Authors
Hu, J., Yu, A., Othmane, B., Qiu, D., Li, H., Li, C., Liu, P., Ren, W., Chen, M., Gong, G., Guo, X., Zhang, H., Chen, J., & Zu, X.
Affiliations
  • Central South University (CN)
  • Texas Medical Center (US)
  • Hunan Provincial People's Hospital (CN)
  • First Affiliated Hospital of University of South China (CN)
Corresponding author
  • Chen, Jinbo
  • Zu, Xiongbing
ORCID
Venue
Theranostics
Publisher
Ivyspring International Publisher
Published
2021
Volume
11
Issue
7
Pages
3089-3108
ISSN
1838-7640 (ISSN-L)
DOI
10.7150/thno.53649
PMC
PMC7847675
OpenAlex
W3119281926
Cited by
387
References
9
Citations by year
2026: 15 · 2025: 44 · 2024: 100 · 2023: 112 · 2022: 94 · 2021: 22
FWCI
31.06
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Theranostics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
Keywords
Siglec-15, bladder cancer, tumor microenvironment, immunotherapy, molecular subtypes, treatment response prediction
MeSH terms
Urinary Bladder Neoplasms, China, Humans, Immunoglobulins, Immunotherapy, Membrane Proteins, Prognosis, Biomarkers, Tumor, Gene Expression, Gene Expression Regulation, Neoplastic, Sequence Analysis, RNA, Disease Progression, Computational Biology, Gene Expression Profiling, Databases, Genetic, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review